Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in BFLY.
← Back to Free Index

BFLY

Analysis as of: 2026-09-28
Butterfly Network, Inc.
Butterfly Network sells handheld ultrasound devices, cloud workflow software, and partner licensing built on its proprietary semiconductor ultrasound technology.
ai hardware healthcare medical devices software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

From Probe Seller to Ultrasound Utility
A real hardware advantage and credible workflow optionality can still support a solid multi-year upside case. The next leg higher, however, requires proof that recurring software and partner economics become durable enough to justify more than a premium device story.

Analysis

Thesis
Butterfly can still create a solid multi-year equity double if it converts a real handheld ultrasound hardware edge into a recurring trust-and-workflow stack, with AI expanding who can scan, where scans happen, and how much software and partner revenue each deployed device supports.
Last Economy Alignment
AI lowers the skill barrier to ultrasound and expands decentralized care, while Butterfly owns the chip, device, and compliance workflow. The cap on the score is that value capture is still partly hardware-led and must deepen into recurring trust and partner economics.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.3x (from 5 most recent analyses)
Reasoning
The upside does not require Butterfly to dominate ultrasound. It requires the company to keep growing probe volume, raise software and partner mix, and prove that compliance, workflow, and embedded royalties make each deployment worth more over time. That can support strong equity compounding even if investors assign a lower sales multiple than today.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is not product viability; it is conversion. Butterfly must prove that non-expert adoption, enterprise workflow attach, and embedded partnerships become durable recurring economics before valuation, partner concentration, and regulatory timing drag it back toward a conventional device multiple.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.41
They control a differentiated ultrasound chip plus the workflow and compliance layers around it, so AI can help more clinicians scan and make each device more valuable. The risk is that hospitals still buy it like a gadget while bigger incumbents and regulatory delays prevent software-like economics from taking hold.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$10.00
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case